eyedrops for presbyopia: phase 3 trials
https://eyewire.news/articles/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia:
“AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, that is being investigated for treating symptoms associated with presbyopia as a topical, once-daily drop delivered by a proprietary vehicle.”
“The proposed mechanism of action of AGN-190584 is through dynamic pupil modulation, an effect in which the iris sphincter is contracted to achieve pupil size reduction in an optimal range. The goal of this pupil size reduction is to increase depth of focus. Secondarily, it is believed to allow for increased accommodation through mild contraction of the ciliary muscle.”